Abstract
The remarkable progresses in stem cell research and cell biological technology over the past decade have assured an exciting future for myocardial regeneration in the treatment of heart failure. In theory, we can regenerate damaged myocardium using in vivo, ex vivo, and in vitro approaches. The in vivo approach accelerates endogenous regeneration, which can be achieved by regulating cardiomyocytes to enter the cell cycle, activating cardiac stem cells, or mobilizing bone marrow stem cells, to repair the injured heart. The ex vivo approach delivers ex vivo treated autologous cells for myocardial regeneration, and includes the implantation of ex vivo expanded autologous skeletal myoblasts, bone marrow stem cells, cardiomyocytes, fibroblasts, or other tissue stem cells. Finally, the in vitro approach can also help to repair the damaged heart by implanting fetal cardiomyocytes or embryo stem cell-derived cardiomyocytes. We give an overview of the experimental studies and clinical applications of myocardial regeneration, and discuss the feasibility and problems associated with the various approaches and plans for myocardial regeneration in the treatment of heart failure.
Keywords: stem cell, cardiomyocyte, myocardial regeneration, approach, cell implantation
Current Cardiology Reviews
Title: Myocardial Regeneration: What is the Best Approach?
Volume: 1 Issue: 2
Author(s): Tao-Sheng Li and Kimikazu Hamano
Affiliation:
Keywords: stem cell, cardiomyocyte, myocardial regeneration, approach, cell implantation
Abstract: The remarkable progresses in stem cell research and cell biological technology over the past decade have assured an exciting future for myocardial regeneration in the treatment of heart failure. In theory, we can regenerate damaged myocardium using in vivo, ex vivo, and in vitro approaches. The in vivo approach accelerates endogenous regeneration, which can be achieved by regulating cardiomyocytes to enter the cell cycle, activating cardiac stem cells, or mobilizing bone marrow stem cells, to repair the injured heart. The ex vivo approach delivers ex vivo treated autologous cells for myocardial regeneration, and includes the implantation of ex vivo expanded autologous skeletal myoblasts, bone marrow stem cells, cardiomyocytes, fibroblasts, or other tissue stem cells. Finally, the in vitro approach can also help to repair the damaged heart by implanting fetal cardiomyocytes or embryo stem cell-derived cardiomyocytes. We give an overview of the experimental studies and clinical applications of myocardial regeneration, and discuss the feasibility and problems associated with the various approaches and plans for myocardial regeneration in the treatment of heart failure.
Export Options
About this article
Cite this article as:
Li Tao-Sheng and Hamano Kimikazu, Myocardial Regeneration: What is the Best Approach?, Current Cardiology Reviews 2005; 1 (2) . https://dx.doi.org/10.2174/1573403054021690
DOI https://dx.doi.org/10.2174/1573403054021690 |
Print ISSN 1573-403X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6557 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches
Current Drug Targets Large A-V Fistula: Pathophysiological Consequences and Therapeutic Perspectives
Current Vascular Pharmacology MicroRNAs in Peripheral Artery Disease
Current Topics in Medicinal Chemistry Postischemic-Anoxic Encephalopathy After Global Forebrain Ischemia
Central Nervous System Agents in Medicinal Chemistry The Cardiac Antihypertrophic Effects of Cyclic GMP-Generating Agents: An Experimental Framework for Novel Treatments of Left Ventricular Remodeling
Vascular Disease Prevention (Discontinued) Q Fever Endocarditis
Infectious Disorders - Drug Targets Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases
Current Medicinal Chemistry An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction
Current Pharmaceutical Design New-Onset Hyperglycemia and Acute Coronary Syndrome: A Systematic Overview and Meta-Analysis
Current Diabetes Reviews Microscopies at the Nanoscale for Nano-Scale Drug Delivery Systems
Current Drug Targets Immunophilins in Nervous System Degeneration and Regeneration
Current Topics in Medicinal Chemistry Vitamin D in Atherosclerosis, Vascular Disease, and Endothelial Function
Current Drug Targets FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Recently Patented Applications of Homologous Cellular and Extracellular Agents as Therapeutics or Targets for the Prevention of Restenosis Post- Angioplasty
Recent Patents on Cardiovascular Drug Discovery Membrane and Soluble Forms of Endoglin in Preeclampsia
Current Molecular Medicine Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?
Current Topics in Medicinal Chemistry The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part I: Epidemiology, Clinical Aspects and Diagnostic Options
Current Cardiology Reviews Spectrum of Radiopharmaceuticals in Nuclear Oncology
Current Cancer Drug Targets